Department of Pathology, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Department of Pathology and Laboratory Medicine, KK Women's and Children's Hospital, Singapore.
Histopathology. 2024 Sep;85(3):371-382. doi: 10.1111/his.15213. Epub 2024 Jun 6.
Human epidermal growth factor receptor 2 (HER2)-enriched breast cancer benefits significantly from anti-HER2 targeted therapies. This highlights the critical need for precise HER2 immunohistochemistry (IHC) interpretation serving as a triage tool for selecting patients for anti-HER2 regimens. Recently, the emerging eligibility of patients with HER2-low breast cancers for a novel HER2-targeted antibody-drug conjugate (T-DXd) adds challenges to HER2 IHC scoring interpretation, notably in the 0-1+ range, which shows high interobserver and interlaboratory staining platform variability. In this review, we navigate evolving challenges and suggest practical recommendations for HER2 IHC interpretation.
人表皮生长因子受体 2（HER2）富集型乳腺癌从抗 HER2 靶向治疗中显著获益。这突出表明，迫切需要进行精确的 HER2 免疫组织化学（IHC）解读，作为筛选接受抗 HER2 方案治疗患者的辅助工具。最近，HER2 低表达乳腺癌患者符合新型 HER2 靶向抗体药物偶联物（T-DXd）的条件，这给 HER2 IHC 评分解读带来了挑战，特别是在 0-1+ 范围内，该范围内显示出观察者间和实验室间染色平台的高度变异性。在本综述中，我们将探讨不断变化的挑战，并为 HER2 IHC 解读提出实用建议。
